Barrett's Esophagus, CIS, HGD
Conditions
Brief summary
Patient's with High Grade Dysplasia, Carcinoma in situ or Early Adenocarcinoma in Barrett's Esophagus are injected with HPPH and one day later are endoscopically treated with light from a laser.
Interventions
DRUGHPPH
3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
Sponsors
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient must have biopsy proven high-grade (severe)dysplasia, carcinoma-in-situ or early stage adenocarcinoma * Patient may have received prior therapy; e.g.Nd-YAG laser, radiation therapy or chemotherapy. At least one-month must have elapsed between prior treatments and PDT * Tumors (HGD/CIS or early adenocarcinoma) can be primary or recurrent, Stage 0 or I N0M (any) * Patients must have no contraindication to endoscopy * Male or female patients must be 18 years old or older. Female patients must not be pregnant and must be practicing a medically acceptable form of birth control or be sterile or post-menopausal. A Pregnancy test is required and must be negative. * Patients must sign an Informed Consent according to FDA guidelines and be acceptable to the RPCI IRB * Patients must have a Karnofsky status 50 or above. * Patients with early invasive adenocarcinoma will be included only if they are considered poor surgical risks, have failed or refused XRT/chemo, or refused surgery. * If the patients has had cancer other than non-melanoma skin cancer, their treating physician must deem them disease-free.
Exclusion criteria
* Patients with tumors of grade greater than T-1. * Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds * WBC\<4000; platelet count\<100,000; prothrombin times 1.5 times above upper normal limit. * Patients with impaired renal and/or hepatic function (total serum bilirubin \> 3.0 mg/d, serum creatinine\>3 mg%, alkaline phosphatase (hepatic) or SGOT\> 3 times the upper normal limit. * Patients on concurrent chemotherapy or radiation therapy will be excluded as well as those having received prior treatment for the esophageal cancer within 4 weeks of enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Optimal Light Dose | 24 hours | Using toxicity to normal surrounding tissue as a determinant and using two HPPH doses of PDT in HGD, CIS or early adenocarcinoma in Barrett's esophagus, to determine the optimal light dose at each HPPH dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity to normal surrounding tissue | 24 hours | To determine the tocixity to normal surrounding tissue of treating at approximately 24 hours(21-26hr) post injection of HPPH |
| Comparing HPPH to Photofrin | 5 years | To determine the length of time of cutaneous photosensitivity of HPPH compared to historical data on Photofrin |
| Effect of injection | 24 hours | To determine the effect of a 24 hours interval between injection of HPPH and light treatment |
| Efficacy of Treatment | 5 years | A secondary objective is to determine efficacy of treatment at each set of paraments, i.e. ability to completely resolve the CIS, HGD or early cancer. |
| Resolve Barrett's mucosa | 5 years | An Additional secondary objective is to determine ability of PDT to resolve the Barrett's mucosa |
Countries
United States
Outcome results
None listed